<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547261</url>
  </required_header>
  <id_info>
    <org_study_id>TED5710</org_study_id>
    <nct_id>NCT00547261</nct_id>
  </id_info>
  <brief_title>Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer</brief_title>
  <official_title>Phase I Dose Escalation and Pharmacokinetic Study of SSR97225 Administered as a 1 Hour IV Infusion D1 Every 3 Weeks (Arm A) or Administered as a 1hour IV Infusion D1, D8, D15 Every 3 Weeks (Arm B) in Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximally tolerated dose and the dose limiting
      toxicity of this antimitotic, tubulin binding investigational drug for those patients who
      have failed standard anticancer treatments.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to lack of supply of the investigational product.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose (MTD) and dose limiting toxicity (DLT)</measure>
    <time_frame>Study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile, antitumor activity in patients with measurable disease, effect of drug on CYP3A4 activity</measure>
    <time_frame>Study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 hour IV infusion D1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 hour IV infusion D1, D8, D15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSR97225</intervention_name>
    <description>every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of metastatic or locally advanced non-hematological cancer

          -  Patients with solid tumors refractory to therapy or for whom no therapy exists

        Exclusion Criteria:

          -  Five or more prior chemotherapy lines for metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt;2

          -  Patients having discontinued previous specific anti-cancer treatment

          -  Patients who have not recovered from all toxic effects from previous specific
             anti-cancer treatment (excluding alopecia)

          -  Patients with abnormal biological/hematological parameters, cardiac abnormalities or
             serious infection/intercurrent illness likely to jeopardize the patient's safety or
             the course of the protocol treatment

          -  No adequate birth control methods

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2007</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>antimitotic</keyword>
  <keyword>tubulin binder</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

